Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Catalyst Pharmaceuticals is a commercial stage biopharmaceutical company focused on rare diseases, aiming to in-license, purchase, and develop products for these conditions [4]. Product Portfolio - The company has two key molecules: FIRDAPSE, which is the only evidence-based product approved for Lambert-Eaton myasthenic syndrome (LEMS), and AGAMREE [5]. Industry Context - The presentation took place at the 44th Annual JPMorgan Healthcare Conference, highlighting the company's engagement with investors and the healthcare community interested in rare diseases [2][3].